Which of the following is not an attribute of amlodipine: A. Generation of an active metabolite B. Large volume of distribution C. High and consistent oral bioavailability D. Long elimination half life

Which of the following is not an attribute of amlodipine:
A. Generation of an active metabolite
B. Large volume of distribution
C. High and consistent oral bioavailability
D. Long elimination half life
by

1 Answer

Answer :

A. Generation of an active metabolit
by

Related questions

Which of the following is not an attribute of amlodipine ? (a) High and consistent oral bioavailability (b) Large volume of distribution (c) Generation of an active metabolite (d) Long elimination half-life

Description : Which of the following is not an attribute of amlodipine ? (a) High and consistent oral bioavailability (b) Large volume of distribution (c) Generation of an active metabolite (d) Long elimination half-life

Last Answer : Ans: C

Among all cardiac glycosides, digoxin is the most commonly used, because: A. It is the most potent and fastest acting glycoside B. It has the highest and most consistent oral bioavailability C. It is the longest acting and the safest glycoside D. It has intermediate plasma half life so that dose adjustments are possible every 2-3 days and toxicity abates rather rapidly after discontinuatio

Description : Among all cardiac glycosides, digoxin is the most commonly used, because: A. It is the most potent and fastest acting glycoside B. It has the highest and most consistent oral ... so that dose adjustments are possible every 2-3 days and toxicity abates rather rapidly after discontinuatio

Last Answer : D. It has intermediate plasma half life so that dose adjustments are possible every 2-3 days and toxicity abates rather rapidly after discontinuatio

If a drug has a constant bioavailability and first order elimination, its maintenance dose rate will be directly proportional to its: A. Volume of distribution B. Plasma protein binding C. Lipid solubility D. Total body clearance

Description : If a drug has a constant bioavailability and first order elimination, its maintenance dose rate will be directly proportional to its: A. Volume of distribution B. Plasma protein binding C. Lipid solubility D. Total body clearance

Last Answer : D. Total body clearance

Tinidazole differs from metronidazole in that: A. It is not active against anaerobic bacteria B. It has a broader spectrum of activity C. It has a longer elimination half life D. It has better oral absorption

Description : Tinidazole differs from metronidazole in that: A. It is not active against anaerobic bacteria B. It has a broader spectrum of activity C. It has a longer elimination half life D. It has better oral absorption

Last Answer : C. It has a longer elimination half life

Which of the following is not a primary/fundamental, but a derived pharmacokinetic parameter: A. Bioavailability B. Volume of distribution C. Clearance D. Plasma half life

Description : Which of the following is not a primary/fundamental, but a derived pharmacokinetic parameter: A. Bioavailability B. Volume of distribution C. Clearance D. Plasma half life

Last Answer : D. Plasma half life

The following is not true of morphine: A. Its 2-glucuronide metabolite is an active analgesic B. Its active metabolite penetrates blood-brain barrier better than morphine C. Its oral: parenteral activity ratio is 1:4 D. It undergoes enterohepatic cycling

Description : The following is not true of morphine: A. Its 2-glucuronide metabolite is an active analgesic B. Its active metabolite penetrates blood-brain barrier better than morphine C. Its oral: parenteral activity ratio is 1:4 D. It undergoes enterohepatic cycling

Last Answer : B. Its active metabolite penetrates blood-brain barrier better than morphine

Select the fluoroquinolone which has high oral bioavailability, longer elimination half-life and which does not inhibit metabolism of theophylline: A. Norfloxacin B. Pefloxacin C. Lomefloxacin D. Ciprofloxacin

Description : Select the fluoroquinolone which has high oral bioavailability, longer elimination half-life and which does not inhibit metabolism of theophylline: A. Norfloxacin B. Pefloxacin C. Lomefloxacin D. Ciprofloxacin

Last Answer : C. Lomefloxacin

If a drug has a constant bioavailability and first order elimination, its maintenance dose rate will be directly proportional to its: A. Volume of distribution B. Plasma protein binding C. Lipid solubility D. Total body clearance

Description : If a drug has a constant bioavailability and first order elimination, its maintenance dose rate will be directly proportional to its: A. Volume of distribution B. Plasma protein binding C. Lipid solubility D. Total body clearance

Last Answer : D. Total body clearanc

Teicoplanin has the following feature(s): A. Antimicrobial activity and indications similar to vancomycin B. Long elimination half-life C. Efficacy in systemic infections by oral route D. Both ‘A’ and ‘B’ are correct

Description : Teicoplanin has the following feature(s): A. Antimicrobial activity and indications similar to vancomycin B. Long elimination half-life C. Efficacy in systemic infections by oral route D. Both ‘A’ and ‘B’ are correct

Last Answer : D. Both ‘A’ and ‘B’ are correct

The following is true of procainamide except: A. It generates an active metabolite in the body B. Its plasma half-life is longer than that of quinidine C. On long-term use, it can cause systemic lupus erythematosus like illness D. It is effective in many cases of ventricular extrasystoles, not responding to lignocaine

Description : The following is true of procainamide except: A. It generates an active metabolite in the body B. Its plasma half-life is longer than that of quinidine C. On long-term use, it ... erythematosus like illness D. It is effective in many cases of ventricular extrasystoles, not responding to lignocaine

Last Answer : A. Disopyramide

Drugs which undergo high degree of first-pass metabolism in liver: A. Have low oral bioavailability B. Are excreted primarily in bile C. Are contraindicated in liver disease D. Exhibit zero order kinetics of elimination

Description : Drugs which undergo high degree of first-pass metabolism in liver: A. Have low oral bioavailability B. Are excreted primarily in bile C. Are contraindicated in liver disease D. Exhibit zero order kinetics of elimination

Last Answer : A. Have low oral bioavailability

Drugs which undergo high degree of first-pass metabolism in liver: A. Have low oral bioavailability B. Are excreted primarily in bile C. Are contraindicated in liver disease D. Exhibit zero order kinetics of elimination

Description : Drugs which undergo high degree of first-pass metabolism in liver: A. Have low oral bioavailability B. Are excreted primarily in bile C. Are contraindicated in liver disease D. Exhibit zero order kinetics of elimination

Last Answer : A. Have low oral bioavailability

The following statement is not true of carbamazepine: A. It generates an active metabolite B. Its plasma half life decreases to nearly half of the original value after chronic use C. It is being used in mania D. It is not effective in complex partial seizures

Description : The following statement is not true of carbamazepine: A. It generates an active metabolite B. Its plasma half life decreases to nearly half of the original value after chronic use C. It is being used in mania D. It is not effective in complex partial seizures

Last Answer : D. It is not effective in complex partial seizures

Carbimazole differs from propylthiouracil in that: A. It is dose to dose less potent B. It has a shorter plasma half life C. It does not produce an active metabolite D. It does not inhibit peripheral conversion of thyroxine to triiodothyronine

Description : Carbimazole differs from propylthiouracil in that: A. It is dose to dose less potent B. It has a shorter plasma half life C. It does not produce an active metabolite D. It does not inhibit peripheral conversion of thyroxine to triiodothyronine

Last Answer : D. It does not inhibit peripheral conversion of thyroxine to triiodothyronine

Low molecular weight heparins have the following advantages over unfractionated heparin except: A. Higher efficacy in arterial thrombosis B. Less frequent dosing C. Higher and more consistent subcutaneous bioavailability D. Laboratory monitoring of response not required

Description : Low molecular weight heparins have the following advantages over unfractionated heparin except: A. Higher efficacy in arterial thrombosis B. Less frequent dosing C. Higher and more consistent subcutaneous bioavailability D. Laboratory monitoring of response not required

Last Answer : A. Higher efficacy in arterial thrombosis

The distinctive features of azithromycin include the following except: A. Efficacy against organisms which have developed resistance to erythromycin B. Marked tissue distribution and intracellular penetration C. Long terminal elimination half-life D. Low propensity to drug interactions due to inhibition of cytochrome P450 enzymes

Description : The distinctive features of azithromycin include the following except: A. Efficacy against organisms which have developed resistance to erythromycin B. Marked tissue distribution and intracellular penetration ... D. Low propensity to drug interactions due to inhibition of cytochrome P450 enzymes

Last Answer : A. Efficacy against organisms which have developed resistance to erythromycin

he dominant pharmacokinetic feature of penicillin G is: A. It is equally distributed extra- and intracellularly B. It is rapidly secreted by proximal renal tubules C. It has low oral bioavailability due to high first pass metabolism in liver D. It does not cross blood–CSF barrier even when meninges are inflamed

Description : he dominant pharmacokinetic feature of penicillin G is: A. It is equally distributed extra- and intracellularly B. It is rapidly secreted by proximal renal tubules C. It has low oral bioavailability ... pass metabolism in liver D. It does not cross blood-CSF barrier even when meninges are inflamed

Last Answer : B. It is rapidly secreted by proximal renal tubules

The distinctive feature(s) of methadone compared to morphine is/are: A. High oral bioavailability B. High plasma protein and tissue binding C. Delayed and milder withdrawal symptoms in dependent subjects D. All of the above

Description : The distinctive feature(s) of methadone compared to morphine is/are: A. High oral bioavailability B. High plasma protein and tissue binding C. Delayed and milder withdrawal symptoms in dependent subjects D. All of the above

Last Answer : D. All of the above

15.45 To be a useful inhaled glucocorticoid the drug should have: A. High oral bioavailability B. Low oral bioavailability C. Additional bronchodilator activity

Description : 15.45 To be a useful inhaled glucocorticoid the drug should have: A. High oral bioavailability B. Low oral bioavailability C. Additional bronchodilator activity

Last Answer : B. Low oral bioavailability

Limitations of typical tricyclic antidepressants include the following except: A. Narrow safety margin B. Low oral bioavailability C. Frequent side effects D. Long latent period for response

Description : Limitations of typical tricyclic antidepressants include the following except: A. Narrow safety margin B. Low oral bioavailability C. Frequent side effects D. Long latent period for response

Last Answer : B. Low oral bioavailability

The following is true of quinine: A. It has a longer elimination half-life than chloroquine B. It is not to be used for prophylaxis of malaria C. It is not active against P. vivax D. It should not be used along with sulfa-pyrimethamine

Description : The following is true of quinine: A. It has a longer elimination half-life than chloroquine B. It is not to be used for prophylaxis of malaria C. It is not active against P. vivax D. It should not be used along with sulfa-pyrimethamine

Last Answer : B. It is not to be used for prophylaxis of malaria

Which of the following is not a primary/fundamental, but a derived pharmacokinetic parameter: A. Bioavailability B. Volume of distribution C. Clearance D. Plasma half life

Description : Which of the following is not a primary/fundamental, but a derived pharmacokinetic parameter: A. Bioavailability B. Volume of distribution C. Clearance D. Plasma half life

Last Answer : D. Plasma half life

Choose the correct statement(s) about cefepime: A. It is a 4th generation cephalosporin B. It is active against many bacteria resistant to 3rd generation celphalosporins C. It is active by the oral route D. Both 'A' and 'B' are correct

Description : Choose the correct statement(s) about cefepime: A. It is a 4th generation cephalosporin B. It is active against many bacteria resistant to 3rd generation celphalosporins C. It is active by the oral route D. Both 'A' and 'B' are correct

Last Answer : D. Both 'A' and 'B' are correct

The high virus selectivity of acyclovir is due to: A. Its preferential uptake by virus infected cells B. Need of virus specific enzyme for its conversion to the active metabolite C. Its action on virus directed reverse transcriptase which does not occur in noninfected cells D. Both ‘A’ and ‘B’ are correct

Description : The high virus selectivity of acyclovir is due to: A. Its preferential uptake by virus infected cells B. Need of virus specific enzyme for its conversion to the active metabolite C. Its action on ... reverse transcriptase which does not occur in noninfected cells D. Both A' and B' are correct

Last Answer : D. Both ‘A’ and ‘B’ are correct

Cefotaxime has the following properties except: A. It is highly active against aerobic gram negative bacteria B. It is the most active cephalosporin against Pseudomonas aeruginosa C. It produces an active metabolite D. It has achieved high cure rates in serious hospital acquired infections

Description : Cefotaxime has the following properties except: A. It is highly active against aerobic gram negative bacteria B. It is the most active cephalosporin against Pseudomonas aeruginosa C. It produces an active metabolite D. It has achieved high cure rates in serious hospital acquired infections

Last Answer : B. It is the most active cephalosporin against Pseudomonas aeruginosa

Ethanol is used in methanol poisoning because it: A. Antagonises the actions of methanol B. Stimulates the metabolism of methanol and reduces its blood level C. Inhibits the metabolism of methanol and generation of toxic metabolite D. Replenishes the folate stores depleted by methano

Description : Ethanol is used in methanol poisoning because it: A. Antagonises the actions of methanol B. Stimulates the metabolism of methanol and reduces its blood level C. Inhibits the metabolism of methanol and generation of toxic metabolite D. Replenishes the folate stores depleted by methano

Last Answer : C. Inhibits the metabolism of methanol and generation of toxic metabolite

N-acetyl cysteine is beneficial in acute paracetamol poisoning because: A. It reacts with paracetamol to form a nontoxic complex B. It inhibits generation of the toxic metabolite of paracetamol C. It is a free radical scavenger D. It replenishes hepatic glutathione which in turn binds the toxic metabolite of paracetamol

Description : N-acetyl cysteine is beneficial in acute paracetamol poisoning because: A. It reacts with paracetamol to form a nontoxic complex B. It inhibits generation of the toxic metabolite of ... scavenger D. It replenishes hepatic glutathione which in turn binds the toxic metabolite of paracetamol

Last Answer : D. It replenishes hepatic glutathione which in turn binds the toxic metabolite of paracetamol

The loading dose of a drug is governed by its: A. Renal clearance B. Plasma half life C. Volume of distribution D. Elimination rate constant

Description : The loading dose of a drug is governed by its: A. Renal clearance B. Plasma half life C. Volume of distribution D. Elimination rate constant

Last Answer : C. Volume of distribution

The loading dose of a drug is governed by its: A. Renal clearance B. Plasma half life C. Volume of distribution D. Elimination rate constant

Description : The loading dose of a drug is governed by its: A. Renal clearance B. Plasma half life C. Volume of distribution D. Elimination rate constant

Last Answer : C. Volume of distribution

Choose the correct statement about famciclovir: A. It is active against acyclovir resistant strains of herpes simplex virus B. It does not need conversion to an active metabolite C. It is used orally to treat genital herpes simplex D. It is the drug of choice for cytomegalovirus retinitis

Description : Choose the correct statement about famciclovir: A. It is active against acyclovir resistant strains of herpes simplex virus B. It does not need conversion to an active metabolite C. It is used orally to treat genital herpes simplex D. It is the drug of choice for cytomegalovirus retinitis

Last Answer : C. It is used orally to treat genital herpes simplex

What is true of isonicotinic acid hydrazide (INH): A. An active transport mechanism concentrates INH inside sensitive mycobacteria B. Sensitive mycobacteria generate an active metabolite of INH through a catalaseperoxidase enzyme C. The most common mechanism of INH resistance is mutation i

Description : What is true of isonicotinic acid hydrazide (INH): A. An active transport mechanism concentrates INH inside sensitive mycobacteria B. Sensitive mycobacteria generate an active metabolite of INH through a catalaseperoxidase enzyme C. The most common mechanism of INH resistance is mutation i

Last Answer : D. Both 'A' and 'B' are correct

In the treatment of parkinsonism, bromocriptine differs from levodopa in the following respects except: A. It does not need conversion to an active metabolite B. It has a longer duration of action C. It activates dopamine D2 receptors, with little/antagonistic action on D1 receptors D. It does not produce behavioral/psychiatric side effect

Description : In the treatment of parkinsonism, bromocriptine differs from levodopa in the following respects except: A. It does not need conversion to an active metabolite B. It has a longer duration of ... with little/antagonistic action on D1 receptors D. It does not produce behavioral/psychiatric side effect

Last Answer : D. It does not produce behavioral/psychiatric side effects

Which of the following is a disease modifying antirheumatic drug whose active metabolite inhibits the enzyme dihydro-orotate dehydrogenase: A. Leflunomide B. Nimesulide C. Sulfasalazine D. Colchicine

Description : Which of the following is a disease modifying antirheumatic drug whose active metabolite inhibits the enzyme dihydro-orotate dehydrogenase: A. Leflunomide B. Nimesulide C. Sulfasalazine D. Colchicine

Last Answer : A. Leflunomide

The following is true of clofazimine except: A. It is cidal to Mycobacterium leprae B. It has additional antiinflammatory property C. It has a very long elimination half life D. It discolours skin and sweat

Description : The following is true of clofazimine except: A. It is cidal to Mycobacterium leprae B. It has additional antiinflammatory property C. It has a very long elimination half life D. It discolours skin and sweat

Last Answer : A. It is cidal to Mycobacterium leprae

Compared to ****/beef insulins, the human insulins: A. Are more potent B. Have a faster kinetics of absorption and elimination C. Have longer biological action half life D. Penetrate blood-brain barrier more efficiently

Description : Compared to pork/beef insulins, the human insulins: A. Are more potent B. Have a faster kinetics of absorption and elimination C. Have longer biological action half life D. Penetrate blood-brain barrier more efficiently

Last Answer : B. Have a faster kinetics of absorption and elimination

If a drug is eliminated by first order kinetics: A. A constant amount of the drug will be eliminated per unit time B. Its clearance value will remain constant C. Its elimination half life will increase with dose D. It will be completely eliminated from the body in 2 × half life period

Description : If a drug is eliminated by first order kinetics: A. A constant amount of the drug will be eliminated per unit time B. Its clearance value will remain constant C. Its elimination half life will increase with dose D. It will be completely eliminated from the body in 2 × half life period

Last Answer : B. Its clearance value will remain constant

The following is true of clarithromycin except: A. It produces less gastric irritation and pain than erythromycin B. It is the most active macrolide antibiotic against Helicobacter pylori C. It does not interact with terfenadine or cisapride to cause cardiac arrhythmias D. It exhibits dose dependent elimination kinetics

Description : The following is true of clarithromycin except: A. It produces less gastric irritation and pain than erythromycin B. It is the most active macrolide antibiotic against Helicobacter pylori ... terfenadine or cisapride to cause cardiac arrhythmias D. It exhibits dose dependent elimination kinetics

Last Answer : C. It does not interact with terfenadine or cisapride to cause cardiac arrhythmias

To be a useful inhaled glucocorticoid the drug should have (a) High oral bioavailability (b) Low oral bioavailability (c) Additional bronchodilator activity (d) Prodrug character

Description : To be a useful inhaled glucocorticoid the drug should have (a) High oral bioavailability (b) Low oral bioavailability (c) Additional bronchodilator activity (d) Prodrug character

Last Answer : Ans: B

The ‘amine’ ergot alkaloid differs from ‘amino acid’ ergot alkaloid in that it has: A. High oral bioavailability B. Better CNS penetrability C. Weaker oxytocic action D. Strong anti-5-HT action

Description : The ‘amine’ ergot alkaloid differs from ‘amino acid’ ergot alkaloid in that it has: A. High oral bioavailability B. Better CNS penetrability C. Weaker oxytocic action D. Strong anti-5-HT action

Last Answer : A. High oral bioavailability

Dihydroergotamine (DHE) differs from ergotamine in the following respect: A. It is a more potent oxytocic B. It has antiemetic property C. It has high oral bioavailability D. It is a more potent α adrenergic blocker and less potent vasoconstrictor

Description : Dihydroergotamine (DHE) differs from ergotamine in the following respect: A. It is a more potent oxytocic B. It has antiemetic property C. It has high oral bioavailability D. It is a more potent α adrenergic blocker and less potent vasoconstrictor

Last Answer : D. It is a more potent α adrenergic blocker and less potent vasoconstrictor

Indicate the attribute that is common to both polymyxin B and bacitracin: A. Both are active against gram negative bacteria B. Both are too toxic for systemic use C. Both act by inhibiting bacterial cell wall synthesis D. Both a

Description : Indicate the attribute that is common to both polymyxin B and bacitracin: A. Both are active against gram negative bacteria B. Both are too toxic for systemic use C. Both act by inhibiting bacterial cell wall synthesis D. Both a

Last Answer : B. Both are too toxic for systemic use

Sustained/controlled release oral dosage form is appropriate for the following type of drug: A. An antiarthritic with a plasma half life of 24 hr B. A sleep inducing hypnotic with a plasma half life of 2 hours C. An antihypertensive with a plasma half life of 3 hours D. An analgesic with a plasma half life of 6 hours used for relief of casual headache

Description : Sustained/controlled release oral dosage form is appropriate for the following type of drug: A. An antiarthritic with a plasma half life of 24 hr B. A sleep inducing hypnotic with a plasma half life of ... 3 hours D. An analgesic with a plasma half life of 6 hours used for relief of casual headache

Last Answer : C. An antihypertensive with a plasma half life of 3 hours

Fluconazole differs from ketoconazole in that: A. It is not active by the oral route B. It is a more potent inhibitor of drug metabolism C. It is not effective in cryptococcal meningitis D. It is unlikely to produce anti-androgenic side effects

Description : Fluconazole differs from ketoconazole in that: A. It is not active by the oral route B. It is a more potent inhibitor of drug metabolism C. It is not effective in cryptococcal meningitis D. It is unlikely to produce anti-androgenic side effects

Last Answer : D. It is unlikely to produce anti-androgenic side effects

The following is not a valid indication for parenteral iron therapy: A. Inadequate response to oral iron due to patient noncompliance B. Anaemia during pregnancy C. Severe anaemia associated with chronic bleeding D. Anaemia in a patient of active rheumatoid arthritis

Description : The following is not a valid indication for parenteral iron therapy: A. Inadequate response to oral iron due to patient noncompliance B. Anaemia during pregnancy C. Severe anaemia associated with chronic bleeding D. Anaemia in a patient of active rheumatoid arthritis

Last Answer : B. Anaemia during pregnancy

Which of the following statements about vancomycin is accurate? (a) It is bacteriostatic (b) It binds to PBPs (c) It is not susceptible to penicillinase (d) It has the advantage of oral bioavailability (e) Staphylococcal enterocolitis occurs commonly with its use

Description : Which of the following statements about vancomycin is accurate? (a) It is bacteriostatic (b) It binds to PBPs (c) It is not susceptible to penicillinase (d) It has the advantage of oral bioavailability (e) Staphylococcal enterocolitis occurs commonly with its use

Last Answer : Ans: C

Bioavailability differences among oral formulations of a drug are most likely to occur if the drug: A. Is freely water soluble B. Is completely absorbed C. Is incompletely absorbed D. Undergoes little first-pass metabolism

Description : Bioavailability differences among oral formulations of a drug are most likely to occur if the drug: A. Is freely water soluble B. Is completely absorbed C. Is incompletely absorbed D. Undergoes little first-pass metabolism

Last Answer : C. Is incompletely absorbed

Bioavailability of drug refers to: A. Percentage of administered dose that reaches systemic circulation in the unchanged form B. Ratio of oral to parenteral dose C. Ratio of orally administered drug to that excreted in the faeces D. Ratio of drug excreted unchanged in urine to that excreted as metabolites

Description : Tricyclic antidepressants can alter the oral absorption of many drugs by: A. Complexing with the other drug in the intestinal lumen B. Altering gut motility C. Altering gut flora D. Damaging gut mucosa

Last Answer : C. Altering gut flora

Bioavailability of drug refers to: A. Percentage of administered dose that reaches systemic circulation in the unchanged form B. Ratio of oral to parenteral dose C. Ratio of orally administered drug to that excreted in the faeces D. Ratio of drug excreted unchanged in urine to that excreted as metabolites

Description : Bioavailability of drug refers to: A. Percentage of administered dose that reaches systemic circulation in the unchanged form B. Ratio of oral to parenteral dose C. Ratio of orally administered drug to ... in the faeces D. Ratio of drug excreted unchanged in urine to that excreted as metabolites

Last Answer : A. Percentage of administered dose that reaches systemic circulation in the unchanged form

Bioavailability differences among oral formulations of a drug are most likely to occur if the drug: A. Is freely water soluble B. Is completely absorbed C. Is incompletely absorbed D. Undergoes little first-pass metabolism

Description : Bioavailability differences among oral formulations of a drug are most likely to occur if the drug: A. Is freely water soluble B. Is completely absorbed C. Is incompletely absorbed D. Undergoes little first-pass metabolism

Last Answer : C. Is incompletely absorbed

Bioavailability of drug refers to: A. Percentage of administered dose that reaches systemic circulation in the unchanged form B. Ratio of oral to parenteral dose C. Ratio of orally administered drug to that excreted in the faeces D. Ratio of drug excreted unchanged in urine to that excreted as metabolites

Description : Bioavailability of drug refers to: A. Percentage of administered dose that reaches systemic circulation in the unchanged form B. Ratio of oral to parenteral dose C. Ratio of orally administered drug to ... in the faeces D. Ratio of drug excreted unchanged in urine to that excreted as metabolites

Last Answer : A. Percentage of administered dose that reaches systemic circulation in the unchanged form